Why the study?
Atherosclerosis is closely linked to renin-angiotensin system activation, but different pathways can mediate pro- or anti-atherogenic outcomes.
Key points are not available for this paper at this time.
Design
Review
Supports trials of ACE2/Ang-1-7 modulators in atherosclerosis; leaves open clinical outcome benefits.
Atherosclerosis is the leading cause of vascular disease worldwide and contributes significantly to deaths from cardiovascular complications. There is a remarkably close relationship between atherosclerotic plaque formation and the activation of renin-angiotensin system (RAS). However, depending on which RAS pathway is activated, pro- or anti-atherogenic outcomes may be observed. This brief review focuses on the role of three of the most important pieces of RAS axis, angiotensin II (Ang-II), angiotensin converting enzyme type 2 (ACE2), and angiotensin 1-7 (Ang-1-7) and their involvement in atherosclerosis. We focused on the effects of these molecules on vascular function and inflammation, which are important determinants of atherogenesis. Furthermore, we highlighted potential pharmacological approaches to treat this disorder.
No takes yet. Share an insight, caveat, or question.
Silva et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: